Q1 2026 saw 13% revenue growth and 30% adjusted EBITA growth, with strong margins led by Assistive Tech and MedTech. Specialty Pharma improved but remains a focus for margin enhancement, while a robust balance sheet supports further acquisitions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.